Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Gastro-oesophageal reflux disease (GERD) is a chronic, relapsing condition – manifesting mostly with heartburn and acid regurgitation – that negatively affects daily quality of life. The two main treatments for GERD are medical – proton pump inhibitors (PPIs) and laparoscopic antireflux surgery (LARS). Both treatments have advantages and side effects that continue to be debated. On one hand, medical therapy may be associated with residual regurgitation and the potential long-term side effects of PPI (eg, osteoporotic fractures, drug–drug interaction). On the other hand, LARS may be associated with technical failures, dysphagia and bloating.
Under the acronym LOTUS, this 5-year randomised study compared efficacy and safety of LARS with ‘optimised’ PPI/oral esomeprazole (ESO) therapy for the long-term management of GERD. LOTUS is an open, parallel group, multicentre, randomised, controlled trial undertaken in expert and …
Competing interests None.